Merck and Co., Inc. v. Hi-Tech Pharmacal Co., Inc.

Case Number: CLB0139

Date: 03.29.2007

Citation: No. 06-1401 (Fed. Cir. 2007)

A term of a patent subject to a terminal disclaimer may be extended, pursuant to 35 U.S.C. § 156, to compensate for delays that occur during regulatory review.

Download PDF

Tagged In:

FDA review Hatch-Waxman patent term extension terminal disclaimer
Return to Case Law Briefs Main Page